Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2003
10/02/2003US20030187036 Use of biguanide derivatives for making a medicine having a wound healing effect
10/02/2003US20030187024 Vision disorders; antiinflammatory agents; autoimmune disease; anticancer qgents; skin disorders
10/02/2003US20030187012 Reduction physical cigarette smoking
10/02/2003US20030187009 Analgesics, diarrhea, anticonvulsants, antitussive agents or drug abuse therapy
10/02/2003US20030187007 Inhibitors of protein kinase for the treatment of disease
10/02/2003US20030187004 Central nervous system disorders; Alzheimer's disease
10/02/2003US20030186996 Angiogenesis inhibitors
10/02/2003US20030186994 Anticholesterol agents; cardiovascular disorders
10/02/2003US20030186989 Antihistamines; respiratory system disorders
10/02/2003US20030186985 Oxyiminoalkanoic acid derivatives
10/02/2003US20030186984 Substituted cyclohexane derivatives
10/02/2003US20030186981 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases
10/02/2003US20030186974 Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
10/02/2003US20030186964 Piperdines for use as orexin receptor antagonists
10/02/2003US20030186941 Cyclopenteneone derivatives
10/02/2003US20030186933 Preparation of aqueous clear solution dosage forms with bile acids
10/02/2003US20030186905 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone3' -untranslated region
10/02/2003US20030186894 Dry powder compositions having improved dispersivity
10/02/2003US20030186891 Polypeptide comprising fragments of matrix extracellular phosphoglycoproteins used to control calcitriol concentrations in cells, for prophylaxis of bone disorders
10/02/2003US20030186871 Contacting a solution comprising an AKR1C polypeptide or fragment with agent, selecting an agent that modulates the expression or catalytic activity of AKR1C polypeptide or fragmet, thereby identifying an agent for therapy of diabetes
10/02/2003US20030186847 Insulin derivatives and synthesis thereof
10/02/2003US20030186842 Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family
10/02/2003US20030186401 Method of recovering pinitol or chiro-inositol in high yield from soy fractions
10/02/2003US20030186337 Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
10/02/2003US20030186325 Method of screening for inhibitors of osteopontin
10/02/2003US20030186321 Comprises polypeptide having antitumor, immunomodulatory and viricidal activity for treating leukemia, hepatitis and autoimmune diseases
10/02/2003US20030186308 Prostacyclin-stimulating factor-2
10/02/2003US20030186244 Using stored nucleotide sequence information to screen genome databases to detect restriction fragment length polymorphisms which are associated with genetic disorders
10/02/2003US20030185916 Method of extracting antioxidants from lamiaceae species and the extract products thereof
10/02/2003US20030185905 Plant extracts for the treatment of increased bone resorption
10/02/2003US20030185893 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
10/02/2003US20030185891 Glycogen phosphorylase inhibitor
10/02/2003US20030185890 Compositions and methods for polynucleotide delivery
10/02/2003US20030185880 Glyburidge composition
10/02/2003US20030185877 Method of producing oily suspensions of water-soluble vitamins
10/02/2003US20030185824 Administering an inhibitor of the CD2/LFA-3 interaction, in combination with an auxiliary agent, such as UV-B
10/02/2003US20030185816 Modified immunogenic self-protein and a surfactant capable of acting as a solubiliser, especially modified human TNF alpha and cetylpyridinium chloride
10/02/2003US20030185815 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/02/2003US20030185791 TNF-derived peptides for use in treating oedema
10/02/2003US20030185789 Lipase inhibiting polymers
10/02/2003US20030185772 Alleviates skin irritation by blending in polypropylene glycol, a specific polar oil, or polybutylene glycol, as well as an ultraviolet absorbent.
10/02/2003US20030183091 Compositions for improving lipid metabolism
10/02/2003CA2488161A1 Novel aminobenzamide derivative
10/02/2003CA2480471A1 A process for the extraction of anthocyanins from black rice and composition thereof
10/02/2003CA2480384A1 Phenanthridinones as parp inhibitors
10/02/2003CA2480302A1 Compositions and methods for treating and preventing necrosis
10/02/2003CA2479898A1 Novel .alpha.-amino-n-(diaminophosphinyl)lactam derivatives
10/02/2003CA2479881A1 Hif hydroxylase inhibitors
10/02/2003CA2479880A1 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003CA2479748A1 Fine particle size pioglitazone
10/02/2003CA2479722A1 Combination of an aldosterone receptor antagonist and a fibric acid derivative
10/02/2003CA2479671A1 Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative
10/02/2003CA2479555A1 Use of cocoa flavanols and oligomers thereof to treat cognitive dysfunction and improve cognitive function in neuro-compromised patients
10/02/2003CA2479338A1 Substituted phenylacetic acids
10/02/2003CA2479259A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003CA2479254A1 Preventive or therapeutic agent for renal disease
10/02/2003CA2478974A1 Inhalable sustained therapeutic formulations
10/02/2003CA2477651A1 Kinase inhibitors
10/02/2003CA2451516A1 Agent for preventing or treating diseases caused by enos expression
10/01/2003EP1348768A2 Method of treatment, diagnosis or detection of diabetes
10/01/2003EP1348707A1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/01/2003EP1348704A1 Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them
10/01/2003EP1348698A1 Substituted carboxylic acid derivatives
10/01/2003EP1348442A1 Antiobestic agents and health foods
10/01/2003EP1348438A1 Compositions comprising d-chiro-inositol for treating hyperlipidemia
10/01/2003EP1348434A1 Use of pyridyl amides as inhibitors of angiogenesis
10/01/2003EP1347990A2 Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
10/01/2003EP1347987A1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
10/01/2003EP1347982A2 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
10/01/2003EP1347981A1 Condensed purine derivatives as a 1? adenosine receptor antagonists
10/01/2003EP1347979A1 Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
10/01/2003EP1347976A2 Tricyclic purine compounds and their analogs as inhibiotrs of cytokine signalling
10/01/2003EP1347972A1 Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
10/01/2003EP1347967A1 Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
10/01/2003EP1347966A1 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
10/01/2003EP1347959A1 Indole derivatives as ligands of thyroid receptors
10/01/2003EP1347762A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
10/01/2003EP1347761A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/01/2003EP1347760A2 Nmda receptor agonist pharmaceutical compositions
10/01/2003EP1347757A2 Method for detoxifying a carbohydrate containing solution
10/01/2003EP1347755A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
10/01/2003EP1347751A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
10/01/2003EP1347748A2 Hydrostatic delivery system for controlled delivery of agent
10/01/2003EP1347746A1 Over-coated chewing gum formulations including tableted center
10/01/2003EP1347745A2 Dietary composition containing conjugated linoleic acid and calcium for improved health
10/01/2003EP1237854B1 Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
10/01/2003EP1204655B1 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
10/01/2003EP1200447B1 Oxazinocarbazoles for the treatment of cns diseases
10/01/2003EP1089996B1 Paroxetine methanesulfonate acetonitrile solvate 1:1
10/01/2003EP1084102B1 New 3-aryl propionic acid derivatives and analogs
10/01/2003EP1037666B1 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
10/01/2003EP1001944B1 Pyrazine derivatives, preparation and medicines containing them
10/01/2003EP1000029B1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
10/01/2003EP0998455B1 Dihomo-seco-cholestanes with two unsaturated bonds in the side chain
10/01/2003EP0662087B1 Method for purifying retinal pigmented epithelium derived neurotrophic factor
10/01/2003CN1446227A Novel fibroblast growth factor (FRF23) and method for use
10/01/2003CN1446218A Benzimidazole derivatives, preparation method and therapeutic use thereof
10/01/2003CN1446214A Cinnoline compounds
10/01/2003CN1446212A Quinoline derivatives having VEGF inhibiting activity
10/01/2003CN1446202A 2-aminopyridine compounds and use thereof as drugs
1 ... 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 ... 1298